Blue Review
A newsletter for physician, professional, facility, ancillary and Medicaid providers

November 2016

Reminder: Pharmacy Program Updates: Quarterly Pharmacy Changes Effective Oct. 1, 2016

Drug List (Formulary) Changes
Based on the availability of new prescription medications and the Prime’s National Pharmacy and Therapeutics Committee’s review of changes in the pharmaceuticals market, some revisions were made to the Blue Cross and Blue Shield of Texas (BCBSTX) Standard drug list and Generics Plus drug list that became effective on Oct. 1, 2016.

Brand Medications Added to the Standard and Generics Plus Drug Lists, Effective Oct. 1, 2016:

Preferred Brand1 Drug Class/Condition Used for
Afstyla Hemophilia

Brand Medications Added to the Standard Drug List, Effective Oct. 1, 2016:

Preferred Brand1 Drug Class/Condition Used for
Impavido Leishmaniasis
Velphoro Anemia

Utilization Management Program Changes
Effective July 1, 2016, the Hetlioz Prior Authorization (PA) program changed its name to: Circadian Rhythm Disorders. All targeted medications and program criteria remained the same. Also, the Kalydeco (Cystic Fibrosis) specialty PA program officially changed its name to: Cystic Fibrosis.

Effective Oct. 1, 2016, several targeted medications were added to the current PA program for select members on standard pharmacy benefit plans.

Targeted drugs added to current pharmacy PA standard programs, effective Oct. 1, 2016:

Drug Category Targeted Medication(s)1,2
Therapeutic Alternatives Cardizem CD, Evzio*, Kazano, Lidocaine patch/ointment, Nesina, Oseni, Sitavig

Targeted mailings were sent to select members affected by PA program changes. For the most up-to-date drug list and list of drug dispensing limits, visit the Pharmacy Program section of our website at bcbstx.com/provider.